The Claim
In glucose-deprived A549 lung adenocarcinoma cells, CEBPB directly binds to the SLC38A2 promoter to activate its transcription, and overexpression of CEBPB restores glutamine utilization and malignant behaviors suppressed by PCK2 knockdown, establishing CEBPB as the direct transcriptional regulator of SLC38A2 downstream of AMPK.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In lung cancer cells deprived of glucose, the protein CEBPB activates the SLC38A2 gene, and increasing CEBPB levels reverses the loss of glutamine use and cancer-like behaviors caused by reducing PCK2.
See the scientific wording
In glucose-deprived A549 lung adenocarcinoma cells, the transcription factor CEBPB directly binds to and activates the SLC38A2 promoter, and its overexpression rescues the loss of glutamine utilization and malignant behaviors caused by PCK2 knockdown, identifying CEBPB as the direct transcriptional regulator of SLC38A2 downstream of AMPK.
When glucose is unavailable, cells activate a protein that turns on another protein, which then switches on a gene that pulls glutamine into the cell. This glutamine feeds a process that keeps energy production going and allows cancer cells to keep growing and spreading.
What the research says
1 studyWhen lung cancer cells are starved of glucose, they rely on glutamine to survive and grow. A protein called CEBPB turns on the gene that lets them take in glutamine. Even if another protein (PCK2) is turned off, forcing CEBPB to stay active brings back glutamine uptake and cancer growth.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.